company background image
ALEC logo

Alector NasdaqGS:ALEC Stock Report

Last Price

US$4.93

Market Cap

US$506.1m

7D

-12.6%

1Y

-25.3%

Updated

25 Sep, 2024

Data

Company Financials +

Alector, Inc.

NasdaqGS:ALEC Stock Report

Market Cap: US$506.1m

ALEC Stock Overview

A clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.

About the company

ALEC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 57.46% per year

Risk Analysis

Volatile share price over the past 3 months
Currently unprofitable and not forecast to become profitable over the next 3 years
Shareholders have been diluted in the past year
Significant insider selling over the past 3 months

Alector, Inc. Competitors

C4 Therapeutics

NasdaqGS:CCCC

US$435.4m

CureVac

NasdaqGM:CVAC

US$693.1m

REGENXBIO

NasdaqGS:RGNX

US$554.0m

Emergent BioSolutions

NYSE:EBS

US$330.1m

Price History & Performance

Summary of all time highs, changes and price drops for Alector
Historical stock prices
Current Share PriceUS$4.93
52 Week HighUS$8.90
52 Week LowUS$3.66
Beta0.68
11 Month Change-7.85%
3 Month Change8.59%
1 Year Change-25.30%
33 Year Change-79.00%
5 Year Change-65.72%
Change since IPO-72.61%

Recent News & Updates

Recent updates

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Jul 11
Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11
Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19
The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02
Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16
Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

AbbVie ends partnership with Alector for Alzheimer’s candidate

Jul 08

Alector: Potential In Neurology And Cancer Treatments

Jun 14

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18
Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27
These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Alector: The GSK Deal Is A Major Value Add

Oct 29

We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate

Sep 27
We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate

Shareholder Returns

ALECUS BiotechsUS Market
7D-12.6%-3.3%1.9%
1Y-25.3%18.7%32.8%

Return vs Industry: ALEC underperformed the US Biotechs industry which returned 18.7% over the past year.

Return vs Market: ALEC underperformed the US Market which returned 32.8% over the past year.

Price Volatility

Is ALEC's price volatile compared to industry and market?
ALEC volatility
ALEC Average Weekly Movement10.1%
Biotechs Industry Average Movement10.1%
Market Average Movement6.3%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: ALEC's share price has been volatile over the past 3 months.

Volatility Over Time: ALEC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013245Arnon Rosenthalwww.alector.com

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease.

Alector, Inc. Fundamentals Summary

How do Alector's earnings and revenue compare to its market cap?
ALEC fundamental statistics
Market capUS$506.07m
Earnings (TTM)-US$160.66m
Revenue (TTM)US$55.28m

8.7x

P/S Ratio

-3.0x

P/E Ratio

Is ALEC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALEC income statement (TTM)
RevenueUS$55.28m
Cost of RevenueUS$191.53m
Gross Profit-US$136.26m
Other ExpensesUS$24.41m
Earnings-US$160.66m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.65
Gross Margin-246.51%
Net Profit Margin-290.66%
Debt/Equity Ratio0%

How did ALEC perform over the long term?

See historical performance and comparison